Tratamientos coadyuvasen en penfigo vulgar.

Reducen en un 29% el riesgo de recaída, pero no ayudan en la inducción de remisión.

Adjuvants Help Reduce Risk of Pemphigus Relapse 

Analysis of 10 trials proves what's been suspected

AUGUST 12, 2015

Adjuvant therapies for pemphigus vulgaris and pemphigus foliaceus have been thought to improve oral glucocorticoid treatment in patients with pemphigus, but it has never been proven. A recent systematic review and meta-analysis of 10 trials involving 559 participants demonstrated that this approach can help reduce the risk of relapse.

Researchers analyzed studies that used the following adjuvants: azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, intravenous immunoglobulin, plasma exchange, and infliximab. Not all medications were included in every analysis, meaning that different adjuvants were pooled together. The primary outcome evaluated was remission; risk of relapse was among several secondary outcomes analyzed. 

The adjuvants did not help lead to remission, but they did decrease the risk of relapse by 29%. 

Citation: Atzmony L, Hodak E, Leshem Y, et al.The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis.  J Am Acad Dermatol. 2015; 73(2):264-271.